In some cases of vestibular schwannoma, a sometimes-lethal tumor often associated with neurofibromatosis 2 (NF2), secretions from the tumor contain toxic molecules that damage the inner ear, shows a new study at Massachusetts Eye and Ear.
The findings, published online in Scientific Reports
, explain why some vestibular schwannomas cause hearing loss even though they are not large enough to compress nearby structures that control hearing. "What's written in textbooks is that these tumors cause hearing loss by growing to the point of compressing the auditory nerve," said senior author Konstantina M. Stankovic, M.D., Ph.D., FACS, an otologic surgeon and researcher at Mass. Eye and Ear. "We knew that it couldn't be as simple as that, because there are large tumors that do not cause hearing loss and little ones that do."
‘Hearing loss is often the first sign of a vestibular schwannoma, though vestibular schwannoma is a hallmark of NF2, a genetic disorder causing tumors to grow throughout the nervous system, the tumors most commonly occur sporadically.’
The researchers also identified TNFa, a toxic compound that has been implicated in other forms of hearing loss, as a causative toxic molecule in the secretions from human vestibular schwannomas. When they applied those secretions directly to a mouse cochlea, they found that the degree of cellular damage correlated to the severity of hearing loss in humans.
Hearing loss is often the first sign of a vestibular schwannoma. Also termed "acoustic neuroma," vestibular schwannomas grow from the Schwann cells of the vestibular (balance) nerve in the inner ear and represent the fourth most common intracranial tumor. Though vestibular schwannoma is a hallmark of NF2, a genetic disorder causing tumors to grow throughout the nervous system, the tumors most commonly occur sporadically.
Although histologically non-malignant, vestibular schwannomas growing in size can damage nearby structures and can lead to death by compressing the brainstem. By compressing nerves in the internal auditory canal, the tumors can cause vestibular dysfunction, facial nerve paralysis and sensorineural hearing loss. Currently, patients with symptomatic or growing vestibular schwannomas can undergo surgical resection of radiotherapy; however, both of these procedures can result in serious complications.
The findings introduce a second way in which the tumors can cause sensorineural hearing loss, by secreting toxic molecules, including TNFa. The authors are hopeful that new therapies may be developed, because there are known ways to inhibit the body's production of TNFa.
"Because these are histologically non-malignant tumors, they do not need to be removed or irradiated as long as they are not growing. However, hearing can continue to decline even in patients with non-growing tumors," Dr. Stankovic said. "Our findings suggest that there may be a pharmacologic way to maintain hearing in some patients with vestibular schwannoma."
This work was supported by the Department of Defense grant W81XWH-14-1-0091, the National Institute of Deafness and Other Communication Disorders grant T32DC00038, Bertarelli Foundation, Nancy Sayles Day Foundation and Lauer Tinnitus Research Center.
Authors of the paper include Sonam Dilwali of Mass. Eye and Ear and the Program in Health, Science and Technology at Harvard and MIT; Lukas Landegger of Mass. Eye and Ear, Harvard Medical School and the Medical University of Vienna; Vitor Soares of Mass. Eye and Ear, Harvard Medical School and the University of Brasilia; Daniel Deschler and Konstantina Stankovic of Mass. Eye and Ear and Harvard Medical School.
About Massachusetts Eye and Ear
Mass. Eye and Ear clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck. Now united with Schepens Eye Research Institute, Mass. Eye and Ear is the world's largest vision and hearing research center, developing new treatments and cures through discovery and innovation. Mass. Eye and Ear is a Harvard Medical School teaching hospital and trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships.
Internationally acclaimed since its founding in 1824, Mass. Eye and Ear employs full-time, board-certified physicians who offer high-quality and affordable specialty care that ranges from the routine to the very complex. U.S. News & World Report's "Best Hospitals Survey" has consistently ranked the Mass. Eye and Ear Departments of Otolaryngology and Ophthalmology as top in the nation.